Please make a donation to the Aplastic Anemia and MDS International Foundation.
Donate Today
Introduction: Paroxysmal nocturnal haemoglobinuria (PNH) is an uncommon, life-threatening disease, caused by intravascular haemolysis by the complement system
Patients at risk for progression from myeloid precursor states (ICUS, CCUS) to MDS are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another (lower- (LR) or higher-risk (HR) disease or leukemia [AML]) are available in the MDS NHS, a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens are collected at baseline and follow-up.
About 25% of patients with myelodysplastic syndromes myelodysplastic syndromes:
Introduction: Myelodysplastic syndromes Myelodysplastic syndromes:
Aside from allogeneic transplantation, the current standard-of-care approach for higher-risk myelodysplastic syndromes
The COMMANDS trial established luspatercept as a first-line treatment for anemia anemia:
To improve the tolerability of posttransplant maintenance and outcomes despite poor-risk disease genetics, we conducted a phase 1 study of venetoclax venetoclax:
Furha Cossor, MD, is a board-certified oncologist and hematologist with Saint Luke's Cancer Specialists. Dr. Cossor has a special interest in multiple myeloma, leukemia, lymphoma, myelodysplastic syndrome, and myeproliferative neoplasms.